Jul 2026
Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance.
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a first-line treatment for epithelial ovarian cancer (EOC) patients, but the development of resistance limits long-term therapeutic efficacy. Tumor acidosis is a hallmark of the tumor microenvironment that has been shown to promote resistance to cancer therapies, sugge...
Kaixin Cheng, Hao Nie, Wei Zhou et al.
· Cancer Research · 0 citations